


10-18-01
6P/1632
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EK102657305US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 17, 2001

Signature: Staci Harris

(Staci Harris)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Claudia Lanari, et al.

Atty. Docket No.: P02004US0

Application No.: 09/613,707

Group Art Unit: 1632

Filed: July 11, 2000

Examiner: R. Shukla

For: MOUSE MAMMARY TUMOR LINES
EXPRESSING ESTROGEN AND
PROGESTERONE RECEPTORS

Box Non-Fee Amendment
Commissioner for Patents
Washington, DC 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed are the following items for filing in connection with the above-referenced Patent Application:

1. Response to Restriction Requirement
2. Preliminary Amendment
3. Return Post Card

Applicants do not believe that any fees are due with this filing. If however, fees are due, please charge them to Deposit Account No. 06-2375, under order no. 10020885, from which the undersigned is authorized to draw.

Dated: October 17, 2001

Respectfully submitted,

By: Melissa W. Acosta

Melissa W. Acosta

Registration No.: 45,872
FULBRIGHT & JAWORSKI L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5407
(713) 651-5246

OCT 24 2001

TECH CENTER 1600/2900

RECEIVED


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EK102657305US, in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 17, 2001

Signature: Staci V. Harris

(Staci V. Harris)

Docket No.: HO-P02004US0
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Claudia Lanari, et al.

Application No.: 09/613,707

Group Art Unit: 1632

Filed: July 11, 2000

Examiner: R. Shukla

For: MOUSE MAMMARY TUMOR LINES
EXPRESSING ESTROGEN AND
PROGESTERONE RECEPTORS

TECH CENTER 1600/2900

OCT 24 2001

RECEIVED

FIRST PRELIMINARY AMENDMENT

Box Non-Fee Amendment
Commissioner for Patents
Washington, DC 20231

Dear Sir:

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EK102657305US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 17, 2001

Signature:

Staci Harris
(Staci Harris)

84
18-24-01
Docket No.: HO-P02004US0
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Claudia Lanari, et al.

Application No.: 09/613,707

Group Art Unit: 1632

Filed: July 11, 2000

Examiner: R. Shukla

For: MOUSE MAMMARY TUMOR LINES
EXPRESSING ESTROGEN AND
PROGESTERONE RECEPTORS

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed September 17, 2001 (Paper No. 7), applicant hereby provisionally elects Group 4, claims 5-8 and claims 11-12 for continued examination, without traverse. Claims 5-8 and 11-12 are drawn to a non-transgenic mouse mammary adenocarcinoma cell line MC7-L1, a kit comprising the cell line and an *in vitro* method for testing the activity of a hormone, anti-hormone etc. using the cells.

Applicants believe that there are no fees due for the filing of this response. If, however, Applicant is in error, then please charge any fees to the standing account of Fulbright & Jaworski L.L.P., Deposit No. 062375 under Order No. 10020885.

Dated: October 17, 2001

Respectfully submitted,

By

Melissa W. Acosta
Melissa W. Acosta

Registration No.: 45,872
FULBRIGHT & JAWORSKI L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5407
(713) 651-5246 fax